514 related articles for article (PubMed ID: 34014424)
1. Myeloid derived suppressor cells and the release of micro-metastases from dormancy.
Khadge S; Cole K; Talmadge JE
Clin Exp Metastasis; 2021 Jun; 38(3):279-293. PubMed ID: 34014424
[TBL] [Abstract][Full Text] [Related]
2. Role of myeloid-derived suppressor cells in metastasis.
Cole K; Pravoverov K; Talmadge JE
Cancer Metastasis Rev; 2021 Jun; 40(2):391-411. PubMed ID: 33411082
[TBL] [Abstract][Full Text] [Related]
3. Role of myeloid-derived suppressor cells in tumor recurrence.
Cole K; Al-Kadhimi Z; Talmadge JE
Cancer Metastasis Rev; 2023 Mar; 42(1):113-142. PubMed ID: 36640224
[TBL] [Abstract][Full Text] [Related]
4. Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment.
Qu P; Wang LZ; Lin PC
Cancer Lett; 2016 Sep; 380(1):253-6. PubMed ID: 26519756
[TBL] [Abstract][Full Text] [Related]
5. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P; Ercolano G; Ianaro A
Front Immunol; 2020; 11():1680. PubMed ID: 32849585
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Dysthe M; Parihar R
Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
[TBL] [Abstract][Full Text] [Related]
7. Understanding the Differentiation, Expansion, Recruitment and Suppressive Activities of Myeloid-Derived Suppressor Cells in Cancers.
Lim HX; Kim TS; Poh CL
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443699
[TBL] [Abstract][Full Text] [Related]
8. Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells.
Payne KK; Keim RC; Graham L; Idowu MO; Wan W; Wang XY; Toor AA; Bear HD; Manjili MH
J Leukoc Biol; 2016 Sep; 100(3):625-35. PubMed ID: 26928306
[TBL] [Abstract][Full Text] [Related]
9. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer.
Toor SM; Elkord E
Immunol Cell Biol; 2018 Oct; 96(9):888-897. PubMed ID: 29635843
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
Front Immunol; 2020; 11():585214. PubMed ID: 33613512
[TBL] [Abstract][Full Text] [Related]
12. Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: an in silico experiment.
Mehdizadeh R; Shariatpanahi SP; Goliaei B; Rüegg C
Sci Rep; 2023 Apr; 13(1):5875. PubMed ID: 37041172
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer.
Song J; Lee J; Kim J; Jo S; Kim YJ; Baek JE; Kwon ES; Lee KP; Yang S; Kwon KS; Kim DU; Kang TH; Park YY; Chang S; Cho HJ; Kim SC; Koh SS; Kim S
Oncotarget; 2016 Aug; 7(32):51840-51853. PubMed ID: 27322081
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease in advanced or metastatic solid cancers: The G0-G1 state and immunotherapy are key to unwinding cancer complexity.
Nicolini A; Rossi G; Ferrari P; Carpi A
Semin Cancer Biol; 2022 Feb; 79():68-82. PubMed ID: 32201368
[TBL] [Abstract][Full Text] [Related]
15. CXCL17-derived CD11b
Hsu YL; Yen MC; Chang WA; Tsai PH; Pan YC; Liao SH; Kuo PL
Breast Cancer Res; 2019 Feb; 21(1):23. PubMed ID: 30755260
[TBL] [Abstract][Full Text] [Related]
16. Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5.
Wang Y; Schafer CC; Hough KP; Tousif S; Duncan SR; Kearney JF; Ponnazhagan S; Hsu HC; Deshane JS
J Immunol; 2018 Jul; 201(1):278-295. PubMed ID: 29752311
[TBL] [Abstract][Full Text] [Related]
17. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
Front Immunol; 2018; 9():398. PubMed ID: 29552012
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
[TBL] [Abstract][Full Text] [Related]
19. MMP-9-cleaved osteopontin isoform mediates tumor immune escape by inducing expansion of myeloid-derived suppressor cells.
Shao L; Zhang B; Wang L; Wu L; Kan Q; Fan K
Biochem Biophys Res Commun; 2017 Dec; 493(4):1478-1484. PubMed ID: 28986261
[TBL] [Abstract][Full Text] [Related]
20. Myeloid-derived suppressor cells and tumor escape from immune surveillance.
Umansky V; Blattner C; Fleming V; Hu X; Gebhardt C; Altevogt P; Utikal J
Semin Immunopathol; 2017 Apr; 39(3):295-305. PubMed ID: 27787613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
